drugset / Trial / NCT03752112

Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis in Non-pregnant Women

NCT03752112

Phase 1/2 Unknown 180 enrolled World Health Organization
RandomizedParallel-groupOpen-labelTreatment

Summary

Hypotheses The antibiotic, Cefixime, for use in non-pregnant women with early syphilis will be efficacious and safe. Primary Objective The primary objective of the study is to demonstrate the efficacy, as measured by a 4 fold decrease in Rapid Plasma Reagin (RPR) titer from baseline to 6 months after treatment, with Cefixime 400mg taken orally two times a day for 10 consecutive days. Secondary Objective The secondary objective of the study is to determine the safety, as measured by the number of grade 3 or greater toxicities experienced, using the NIH/NCI toxicity score, during or after treatment with Cefixime 400mg taken orally two times a day for 10 consecutive days.

Timeline

Start
2019-11-22
Primary completion
2021-03-30
Completion
2021-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Benzathine Penicillin Small molecule 2.4e+06 iu Intramuscular
Subject Cefixime Other / unclassified 400 mg Oral

Indications